DaVita (NYSE:DVA – Get Free Report) released its earnings results on Tuesday. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17), Briefing.com reports. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the firm posted $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. DaVita updated its FY24 guidance to $9.25-$10.05 EPS and its FY 2024 guidance to 9.250-10.050 EPS.
DaVita Stock Performance
Shares of DVA stock traded down $17.37 during trading hours on Wednesday, reaching $140.94. The stock had a trading volume of 1,983,759 shares, compared to its average volume of 810,950. The firm has a market capitalization of $11.82 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. The firm has a 50-day simple moving average of $158.40 and a 200-day simple moving average of $146.05. DaVita has a twelve month low of $76.17 and a twelve month high of $168.50. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.
Insider Buying and Selling at DaVita
In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock valued at $27,387,069 in the last ninety days. Company insiders own 2.00% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on DVA
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Airline Stocks – Top Airline Stocks to Buy Now
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Stock Analyst Ratings and Canadian Analyst Ratings
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.